INS and cancer: The findings indicate a statistically significant reduction in cancer risk when comparing GLP‐1RAs to TZD, with a RR of 0.82 [95% CI: 0.68, 0.96], and to insulin, with a RR of 0.57 [95% CI: 0.32, 0.81].